Needham downgrades Arena Pharmaceuticals (Nasdaq: ARNA) to Hold. BLOOM Trial meets Primary Endpoint, but results may not be strong enough ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE